Background Sodium-glucose cotransporter-2 inhibitors (SGLT2is) represent a new class of
oral hypoglycemic agents used in the treatment of type 2 diabetes mellitus. They have a …

Findings from the past 10 years have placed the glucagon-secreting pancreatic α-cell centre
stage in the development of diabetes mellitus, a disease affecting almost one in every ten …

In a healthy person, the kidney filters nearly 200 g of glucose per day, almost all of which is
reabsorbed. The primary transporter responsible for renal glucose reabsorption is sodium …

Patients with type 2 diabetes (T2DM) have a significantly higher risk of developing
cardiovascular disease (CVD)—namely myocardial infarction, heart failure, and stroke …

Introduction: Type 2 diabetes mellitus (T2DM) is a complex metabolic disorder associated
with high cardiovascular (CV) risk. Some of the therapeutic strategies are contraindicated in …

Future targets are a promising prospect to overcome the limitation of conventional and
current approaches by providing secure and effective treatment without compromising …

An external file that holds a picture, illustration, etc. Object name is bi-8-305-g009. jpg
Introduction: Oral drug delivery is the most favored route of drug administration. However …

Objective (s): Empagliflozin, a sodium-glucose cotransporter-2 (SGLT-2) inhibitor,
possesses verified anti-inflammatory and anti-oxidative stress effects against diabetic …

Aims The present study aims to determine the effects of sodium‐glucose cotransporter 2
(SGLT‐2) inhibitors on the serum uric acid (SUA) levels of patients with type 2 diabetes …

Glucose homeostasis is maintained by antagonistic hormones such as insulin and glucagon
as well as by regulation of glucose absorption, gluconeogenesis, biosynthesis and …